A significant correlation with patient survival was also found for SFRP2, showing a lower median OS (23.8 months, 95% CI 14.7–32.9 months) for patients with a high expression of SFRP2 in their tumour cells (cutoff: 294.3; n = 24/460, 5.2%) as compared to the median OS time (44.0 months, 95% CI 39.1–48.9 months) for patients with a low expression (n = 436, 94.8%). The gene discussed is SFRP2; the disease is neoplasm.